Protecting patients and the planet
At Chiesi, we believe true ‘sustainability’ in respiratory care can only be achieved with a broad array of projects that protect both our patients and the planet. This holistic approach means we sometimes see things a little differently than other pharmaceutical companies.
Inhaler device type matters
There are many considerations when deciding on the right inhaler device. We know environmental impact is one of them, but factors like age, coordination or comorbidities can all lead to difficulties and critical errors,1,2 which can subsequently lead to poor disease control.3,4 Enforced switching of stable patients can also result in worsening of symptoms and an increased use of healthcare resources.4
Inhalers contribute less than 0.1% of global greenhouse gases,4–6 therefore we at Chiesi believe other innovation opportunities should be prioritised and can play a vital role in helping to protect the environment.7–9
Patient health must always be at the centre of decision-making
It is important that both pMDIs and DPIs remain an option for patients depending on their needs. The choice of inhaler device should be the result of an informed discussion between a healthcare professional (HCP) and their patient.10
Whether that’s a pMDI or a DPI, we want to support HCPs in their choice.
How are we helping build a better future?
We take sustainability seriously and challenge ourselves to do more than the expected. Our ongoing projects include:
- Pledging to become carbon neutral by 2035 by offsetting all greenhouse gas emissions generated by Chiesi – well ahead of the UK national target of 20508
- Continuously working to reduce the environmental impact of respiratory treatments, from becoming one of the first pharmaceutical companies to move away from chlorofluorocarbons (CFCs) to continuing to invest millions in low global warming potential innovations to treat respiratory diseases8
- Supporting the NHS strategy to reduce medical waste and empowering patients to change the way they dispose of inhalers by returning them to local pharmacies9
- Avoiding ‘one size fits all’ solutions and ensuring patients have access to the treatments and information they need
Our approach to sustainability may surprise you.
DPI Dry powder inhaler
pMDI Pressurised metered dose inhalers
- Price D et al. Inhaler errors in the CRITIKAL study: Type, Frequency, and Association with Asthma Outcomes. J Allergy Clin Immunol Pract. 2017; 5(4): 1071–1081.
- Usmani OS. Choosing the right inhaler for your asthma or COPD patient. Ther Clin Risk Manag. 2019; 15: 461–472.
- Melani AS et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011; 105(6): 930–938.
- Panigone S et al. An environmentally sustainable patient centred solution for asthma and COPD. Pulmonary & Nasal Drug Delivery. On Drug Delivery. 2020; 106: 14–19.
- The Intergovernmental Panel on Climate Change. AR5 Climate Change 2014: Mitigation of Climate Change. Available at: https://www.ipcc.ch/site/assets/uploads/2018/02/ipcc_wg3_ar5_full.pdf. Accessed March 2021.
- OzonAction Kigali Fact Sheet 2 OzonAction Current Use of HCFCs and HFCs. Available at: http://wedocs.unep.org/bitstream/handle/20.500.11822/26867/7877FS02_C_Uses_EN.pdf?sequence=1&isAllowed=y. Accessed March 2021.
- House of Commons Environmental Audit Committee. UK Progress on Reducing F-gas Emissions. 18 April 2018. Available at: https://publications.parliament.uk/pa/cm201719/cmselect/cmenvaud/469/469.pdf. Accessed March 2021.
- The way we act. Chiesi Sustainability Report 2019. Available at: https://www.chiesi.uk.com/pdf/Chiesi_Sustainability_Report_2019_ENG.pdf. Accessed March 2021.
- NHS Long Term Plan. January 2019. Available at: https://www.longtermplan.nhs.uk/wp-content/uploads/2019/08/nhs-long-term-plan-version-1.2.pdf. Accessed March 2021.
- Kaplan A, Price D. Matching inhaler devices with patients: the role of the primary care physician. Can Respir J. 2018; 9473051.
UK-CHI-2100060. March 2021.